Feasibility of next-generation sequencing test for patients with advanced NSCLC in clinical practice

he usefulness of the Oncomine Dx Target test (Oncomine Dx), a next‐generation sequencing (NGS) test, has already been proven in clinical trials. However, NGS requires high‐quality tumor samples and takes a long time to generate results. The usefulness of a next‐generation sequencing (NGS) test has been proven in clinical trials. The feasibility of NGS is lower than other diagnostics in clinical practice especially with regard to nonsurgical biopsy. It is necessary to improve the feasibility of NGS in clinical practice. To improve NGS feasibility, turnaround time must be shortened, and larger samples must be obtained during surgical procedures. READ ARTICLE

Thoracic Cancer DOI: 10.1111/1759-7714.13786

Authors: Ariyasu R, Uchibori K, Ninomiya H, Ogusu S, Tsugitomi R, Manabe R, Sakamaoto H, Tozuka T, Yoshida H, Amino Y, Kitazono S, Yanagitani N, Takeuchi K, Nishio M.

Real-World OutcomesKirk SmithFebruary 12, 2021ALK-immunohistochemistry, Cobas EGFR mutation test, Oncomine Dx Target test, real-world analysis, turnaround time